Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

Neurology

Volumn 71, Issue 2, 2008, Pages 114-121

  Silberstein, S D ^a   Mannix, L K ^b   Goldstein, J ^c   Couch, J R ^d   Byrd, S C ^e   Ames, M H ^e   McDonald, S A ^e   Lener, S E ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Headache Associates   (United States)

^c San Francisco Clinical Research Center   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOTAMINE; NAPROXEN PLUS SUMATRIPTAN; NAPROXEN; SUMATRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPILEPTIC AURA; HEADACHE; HUMAN; MIGRAINE; NAUSEA; NECK PAIN; PAIN; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS PAIN; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAPROXEN; NAUSEA; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 47549103590     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000316800.22949.20     Document Type: Article

References (43)

1. Carpay J, Schoenen J, Faiz A, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 2004;26:214-223.
2. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 2003;78:1214-1222.
3. Landy S, Savani N, Shackelford S, et al. Efficacy and toler-ability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004;58:913-919.
4. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmi-triptan while pain is mild. Cephalalgia 2004;24:918-924.
5. Loder E, Freitag FG, Adelman J, Pearlman S, Abu-Sakra S. Zolmitriptan study 014 group. Pain-free rates with zolmi-triptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Curr Med Res Opin 2005;21:381-389.
6. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005;25:735-742.
7. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther 2005;27:1785-1794.
8. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 2004;24: 925-933.
9. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004 24(suppl 2):2-7.
10. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovas-cular neurons mediates the antimigraine action of 5HT1B1D receptor agonists. Proc Natl Acad Sci U S A 2004;101:4272-4279.
11. Burstein R, Collins B, Jakubowski M. Defeating Migraine Pain with Triptans: A Race against the Development of Cutaneous Allodynia. Ann Neurol 2004;55:19-26.
12. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001; 24:450-455.
13. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: New players in pain. Pain 2001;93:201-205.
14. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005;64:S9-S15.
15. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005;45:850-861.
16. Burstein R, Jakubowski M, Levy D. Naproxen suppresses sensitization in central trigeminovascular neurons: implication for migraine therapy. Neurology 2006;66:A69.
17. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:1443-1454.
18. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(suppl 1): 1-160.
19. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:935-940.
20. Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed "sinus" headache. Arch Intern Med 2004;164:1769-1772.
21. Levine HL, Setzen M, Cady RK, et al. An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headache. Otolaryngol Head Neck Surg 2006;134:516-523.
22. Eross E, Dodick D, Eross M. The Sinus, Allergy and Migraine Study (SAMS). Headache 2007;47:213-224.
23. Kaniecki R, Ruoff G, Smith T, et al. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. Curr Med Res Opin 2006;22:1535-1544.
24. Kaniecki RG, Totten J. Cervicalgia in migraine: prevalence, clinical characteristics, and response to treatment. Cephalalgia 2001;21:296-297.
25. Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:99-109.
26. Ferrari MD. Should we advise patients to treat migraine attacks early: methodological issues. Eur Neurol 2005; 53(suppl 1):17-21.
27. D'Amico D, Moschiano F, Usai S, Bussone G. Treatment strategies in the acute treatment of migraine: stratified care and early intervention. Neurol Sci 2006;27(suppl 2): S117-S122.
28. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second addition. Cephalalgia 2000;20:765-786.
29. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006;46:914-924.
30. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005;25:735-742.
31. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(suppl 2):s20-s26.
32. Barbanti P, Fabbrini G. Migraine and the extrapyramidal system. Cephalalgia 2002;22:2-11.
33. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:1443-1454.
34. Fox AW, Keywood C, Sheftell FD, Spierings ELH, Winner P. Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT1B/1D agonist efficacy in migraine. Headache 2002;42:680-688.
35. Goadsby PJ, Ferrari MD, Lipton RB. Therapeutic gain or therapeutic ratio? Headache 2003;43:814-815; author reply 815-816.
36. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature: XIX: Applying clinical trial results B Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-1377.
37. Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 2008;71:114-121.
38. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45:983-991.
39. Available at: www.drugstore.com and www.shopping.com. Accessed August 1, 2008.
40. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther 2005;27:1785-1794.
41. Fox AW, Keywood C, Sheftell FD, Spierings ELH, Winner P. Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT1B/1D agonist efficacy in migraine. Headache 2002;42:680-688.
42. Goadsby PJ, Ferrari MD, Lipton RB. Therapeutic gain or therapeutic ratio? Headache 2003;43:814-815; author reply 815-816.
43. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature: XIX: applying clinical trial results B Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-1377.